Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
Fox News
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts weigh the pros and cons of the practice.
Ozempic is approved for type 2 diabetes, while its counterpart, Wegovy, is approved for treating obesity. Both are made by Novo Nordisk. "Health care clinicians do not typically recommend this approach." "Some individuals might start with microdoses to gradually acclimate their body to the medication."
Eli Lilly also offers a diabetes medication, Mounjaro, as well as a version for weight loss, Zepbound.
More Related News